As a member of the cysteine protease family, legumain (LGMN) augments the occurrence and development of atherosclerosis, pulmonary hypertension, peripheral vascular disease, aortic aneurysm and dissection, and promotes the outcome of coronary heart disease. Here, LGMN is linked to pulmonary arterial hypertension.